Future therapeutic options for celiac disease

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 2, Issue 3, 2005, Pages 140-147

  Sollid, Ludvig M ^a   Khosla, Chaitan ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Celiac disease; Gluten; T cells; Therapy; Tissue transglutaminase

Indexed keywords

ALPHA4 INTEGRIN; AT 1001; CELL ADHESION MOLECULE; CYTOKINE; DANSYLCADAVERINE; ENZYME INHIBITOR; GAMMA INTERFERON; GLUTEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 15; KCC 009; L 682777; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; NATURAL KILLER CELL RECEPTOR NKG2D; PROLYL ENDOPEPTIDASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE INHIBITOR; PROTEINASE; RECOMBINANT INTERLEUKIN 10; SB 683699; UNCLASSIFIED DRUG;

BARLEY; CELIAC DISEASE; CLINICAL TRIAL; CROHN DISEASE; DEAMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME THERAPY; GLUTEN FREE DIET; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATION; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RYE; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS; WHEAT;

CELIAC DISEASE; CYTOKINES; DIETARY SUPPLEMENTS; GLUTEN; HUMANS; LYMPHOCYTE ACTIVATION; PEPTIDE HYDROLASES; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 20444489227     PISSN: 17434378     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpgasthep0111     Document Type: Review

References (51)

1. Mäki M et al. (2003) Prevalence of celiac disease among children in Finland. N Engl J Med 348: 2517-2524
2. Sollid LM (2002) Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2: 647-655
3. Hausch F et al. (2002) Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 283: G996-G1003
4. Vanhoof G et al. (1994) Cloning and sequence analysis of the gene encoding human lymphocyte prolyl endopeptidase. Gene 149: 363-366
5. Shan L et al. (2002) Structural basis for gluten intolerance in celiac sprue. Science 297: 2275-2279
6. Piper JL et al. (2004) Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo. J Pharmacol Exp Ther 311: 213-219
7. Shan L et al. (2004) Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J 383: 311-318
8. Marti T et al. (2005) Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J Pharmacol Exp Ther 312: 19-26
9. Chen YS et al. (2003) Identification and characterization of Lactobacillus helveticus PepO2, an endopeptidase with post-proline specificity. Appl Environ Microbiol 69: 1276-1282
10. Zhang N and Jones BL (1996) Purification and partial characterization of a 31-kDa cysteine endopeptidase from germinated barley. Planta 199: 565-572
11. Di Cagno R et al. (2002) Proteolysis by sourdough lactic acid bacteria: effects on wheat flour protein fractions and gliadin peptides involved in human cereal intolerance. Appl Environ Microbiol 68: 623-633
12. Di Cagno R et al. (2004) Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol 70: 1088-1096
13. Molberg Ø et al. (2001) T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol 31: 1317-1323
14. Vader W et al. (2002) The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 122: 1729-1737
15. Arentz-Hansen H et al. (2002) Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 123: 803-809
16. De Laurenzi V and Melino G (2001) Gene disruption of tissue transglutaminase. Mol Cell Biol 21: 148-155
17. Nanda N et al. (2001) Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 276: 20673-20678
18. Szondy Z et al. (2003) Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc Natl Acad Sci USA 100: 7812-7817
19. Choi et al. (2005) Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem. Biol., in press
20. Kim CY et al. (2004) Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 101: 4175-4179
21. Chatenoud L (2003) CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 3: 123-132
22. Burkly LC (2001) CD40 pathway blockade as an approach to immunotherapy. Adv Exp Med Biol 489: 135-152
23. Appel H et al. (2001) Anergy induction by dimeric TCR ligands. J Immunol 166: 5279-5285.
24. Maurano F et al. (2001) Intranasal administration of one alpha gliadin can downregulate the immune response to whole gliadin in mice. Scand J Immunol 53: 290-295
25. Salvati VM et al. (2005) Recombinant human IL-10 suppresses gliadin dependent T cell activation in ex vivo cultured celiac intestinal mucosa. Gut 54: 46-53
26. Mulder CJ et al. (2001) A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur J Gastroenterol Hepatol 13: 1183-1188
27. Nilsen EM et al. (1995) Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut 37: 766-776
28. Maiuri L et al. (2003) Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 362: 30-37
29. Hüe S et al. (2004) A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21: 367-377
30. Maiuri L et al. (2000) Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 119: 996-1006
31. Mention JJ et al. (2003) Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 125: 730-745
32. Meresse B et al. (2004) Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21: 357-366
33. Ogasawara K et al. (2004) NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20: 757-767
34. Fasano A et al. (2000) Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 355: 1518-1519
35. Molberg Ø et al. Mapping of gluten T cell epitopes in the bread wheat ancestors; implications for celiac disease. Gastroenterology, in press
36. Vader LW et al. (2003) Characterization of cereal toxicity for celiac disease patients based on protein homology in grains. Gastroenterology 125: 1105-1113
37. Sjöström H et al. (1998) Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition. Scand J Immunol 48: 111-115
38. Lundin KE et al. (1993) Gliadin-specific, HLA-DQ(α1*0501, β1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 178: 187-196
39. Molberg Ø et al. (1998) Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 4: 713-717
40. van de Wal Y et al. (1998) Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 161: 1585-1588
41. Vader LW et al. (2002) Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med 195: 643-649
42. Forsberg G et al. (2002) Paradoxical coexpression of proinflammatory and down-regulatory cytokines in intestinal T cells in childhood celiac disease. Gastroenterology 123: 667-678
43. Clemente MG et al. (2003) Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 52: 218-223
44. Colombel JF et al. (2001) Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49: 42-46
45. Yasuda H and Wen L (2004) Prevention of autoimmune diabetes by dendritic cells treated with IL-10 [abstract 358-OR]. Diabetes 53
46. Villadsen LS et al. (2002) HuMax-IL15 reduces the severity of psoriasis in human skin grafts transplanted on to SCID mice. Brit J Dermatol 147: 1064
47. Ferrari-Lacraz S et al. (2004) Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol 173: 5818-5826
48. Hommes et al. (2004) Fontolizumab (HuZAF), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease. Gastroenterology 127: 332
49. Arulanandam T (2004) Biological characterisitics of anti-alpha4 intergrin monoclonal antibody (natalizumab) a selective adhesion molecule (SAM) inhibitor for the treatment of multiple sclerosis and Crohn's disease [SA23]. Inflamm Res 53: 3
50. Feagan B et al. (2003) A randomized, double-blind, placebo-controlled trial of iv MLN-02 in 181 patients with moderately active ulcerative colitis is reported. Am J Gastroenterol 98: s248-s249
51. Fasano A (2002) Peptide antagonists of zonulin and methods for use of the same. US patent 6,548,925